Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announces that the Company has entered into a definitive merger agreement, dated October 22, 2024 (the “Merger Agreement”) whereby Double Point Ventures LLC (“DPV”) will acquire 100% of Lumos Pharma’s outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable, unsecured Contingent Value Right (“CVR”) per share payable on achievement of certain milestones (the “Offer”).
Read the full article: Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures //
Source: https://www.globenewswire.com/news-release/2024/10/23/2967721/15114/en/Lumos-Pharma-Enters-into-Definitive-Merger-Agreement-with-Double-Point-Ventures-to-Go-Private-via-a-Tender-Offer-of-4-25-Cash-per-Share-Plus-Contingent-Value-Rights-CVR.html